登入
選單
返回
Google圖書搜尋
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion
Laurent Garderet
Dimitris Ziagkos
Anja van Biezen
Simona Iacobelli
Jürgen Finke
Johan Maertens
Liisa Volin
Per Ljungman
Patrice Chevallier
Jakob R. Passweg
Nicolaas Schaap
Dietrich W. Beelen
Arnon Nagler
Didier Blaise
Xavier Poiré
Ibrahim Yakoub-Agha
Stig Lenhoff
Charles Craddock
Rik Schots
Alessandro Rambaldi
Jaime Sanz
Pavel Jindra
Ghulam Mufti
Marie Robin
Nicolaus Kröger
出版
Universität
, 2018
URL
http://books.google.com.hk/books?id=1_OazwEACAAJ&hl=&source=gbs_api
註釋
Abstract: The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P